Tools for Practice Outils pour la pratique


#186 Doxylamine and Pyridoxine for Nausea and Vomiting of Pregnancy: A review of “retch”ed evidence


CLINICAL QUESTION
QUESTION CLINIQUE
 What is the safety and efficacy of doxylamine/pyridoxine (Diclectin®) in nausea and vomiting of pregnancy?

BOTTOM LINE
RÉSULTAT FINAL
 Doxylamine/B6 appears safe short-term and may be slightly better than placebo in reducing nausea and vomiting in pregnancy (~1 point better on 15-point scale). B6 alone may have similar effect on nausea but other effects unclear. Results are at high risk of bias due to initially undeclared industry support and methodological concerns.   


CFPCLearn Logo

Reading Tools for Practice Article can earn you MainPro+ Credits

La lecture d'articles d'outils de pratique peut vous permettre de gagner des crédits MainPro+

 Join Now S’inscrire maintenant

Already a CFPCLearn Member? Log in

Déjà abonné à CMFCApprendre? Ouvrir une session


EVIDENCE
DONNÉES PROBANTES
 Safety:  
  • Five systematic reviews of 22-37 observational studies (17,000-50,000 pregnant women) exposed to antihistamines like doxylamine.1-5 Many authors have industry affiliations.1,3-5    
    • No reliable effect on malformations with doxylamine.1-5  
Efficacy:  
  • Four systematic reviews:6-9 Not discussed as did not include largest Randomized Controlled Trail (RCT), published 2017.10 
  • 2017 publication of 1970s industry-sponsored (eight arm) RCT: 2,359 women of doxylamine, B6, and dicylomine alone or in various combinations, or placebo, for seven days.10  
    • Percent improvement from baseline for doxylamine/B6 versus placebo, statistically significant:   
      • ≥Moderate undefined “effectiveness” (78% versus 57%).  
      • Nausea (75% versus 52%); not vomiting. 
      • Patients rated doxylamine/B6 better on nausea and vomiting.  
    • B6 alone better than placebo for nausea (68% versus 52%), but not statistically better for vomiting, overall effectiveness or patient ratings.  
    • Drowsiness: 5.6% versus 3% (placebo), Number Needed to Harm=38. 
    • Limitations: Only 66% completed study, questionable data integrity, possible selective reporting. 
  • Industry-sponsored RCT (259 women) of doxylamine/B6 or placebo.11  
    • ~1-point decrease in 15-point nausea/vomiting scale at day 15.  
    • No change in individual nausea, vomiting, retching scores.12  
  • US RCT (36 women) found ondansetron superior to doxylamine/B6 in reducing nausea (3 out of 10-point scale better) but not vomiting.13 
    • Limitations: Used ½ dose doxylamine. 
  • Older studies less reliable.6 
Context: 
  • Disclosed and undisclosed conflicts of interest raise concerns around some of the analysis and reporting of doxylamine/B6 research.14 
  • Cochrane review states “lack of high quality evidence to support any particular intervention”, including doxylamine/B6, B6 alone, metoclopramide, or ginger.6 
  • Guidelines recommend first-line: Antihistamines, phenothiazines (like prochlorperazine), or ginger (UK),15 B6 alone (US),16 or doxylamine/B6 (US, Canada).16,17

Latest Tools for Practice
Derniers outils pour la pratique
program image
Émélie Braschi MD PhD CCFP

#378 Tony Romo-sozumab: Winning touchdown in osteoporosis or interception for the loss?

What is the efficacy and safety of romosozumab in postmenopausal women with osteoporosis?
Read Lire 0.25 credits available Crédits disponibles
program image
Adrienne J Lindblad BSP ACPR PharmD

#377 How to slow the flow IV: Combined oral contraceptives

In premenopausal heavy menstrual bleeding due to benign etiology, do combined oral contraceptives (COC) improve patient outcomes?
Read Lire 0.25 credits available Crédits disponibles
program image
Jennifer Potter MD CCFP

#376 Testosterone supplementation for cis-gender men: Let’s (andro-)pause for a moment (Update)

What are the benefits and harms of testosterone supplementation in healthy cis-gender men or those with age-related low testosterone?
Read Lire 0.25 credits available Crédits disponibles
May 1, 2017

This content is certified for MainPro+ Credits, log in to access

Ce contenu est certifié pour les crédits MainPro+, Ouvrir une session
Author(s)
Auteur(s)
  • Adrienne J Lindblad BSP ACPR PharmD
  • Sudha Koppula MD MCISc CCFP FCFP

1. Seto A, Einarson T, Koren G. Am J Perinatol. 1997 Mar; 14(3):119-24.

2. Chin JW, Gregor S, Persaud N. Am J Perinatol. 2014 Sep; 31(8):701-10.

3. Etwel F, Faught LH, Rieder MJ, et al. Drug Saf. 2017 Feb; 40(2):121-32.

4. Mazzotta P, Magee LA. Drugs. 2000 Apr; 59(4):781-800.

5. McKeigue PM, Lamm SH, Linn S, et al. Teratology. 1994 Jul; 50(1):27-37.

6. Matthews A, Haas DM, O'Mathúna DP, et al. Cochrane Database Syst Rev. 2015 Sep 8; (9):CD007575.

7. Festin M. BMJ Clin Evid. 2014 Mar 19; 2014. pii: 1405.

8. McParlin C, O'Donnell A, Robson SC, et al. JAMA. 2016 Oct 4; 316(13):1392-401.

9. O'Donnell A, McParlin C, Robson SC, et al. Health Technol Assess. 2016 Oct; 20(74):1-268.

10. Zhang R, Persaud N. PLoS One. 2017; 12(1):e0167609.

11. Koren G, Clark S, Hankins GDV, et al. Am J Obstet Gynecol. 2010; 203:571.e1-7.

12. Koren G, Hankins GDV, Caritis SN, et al. Am J Obstet Gynecol (research letter). 2016; 214:664-6.

13. Oliveira LG, Capp SM, You WB, et al. Obstet Gynecol. 2014; 124:735-42.

14. Pimlott N, Kvern B, Woollard R. Can Fam Physician. 2017; 63:13-4.

15. RCOG Green-top Guideline No. 69. June 2016. Available at: https://www.rcog.org.uk/globalassets/documents/guidelines/green-top-guidelines/gtg69-hyperemesis.pdf. Last Accessed: March 8, 2017.

16. [No authors listed]. Obstet Gynecol. 2015; 126(3):e12-24.

17. Campbell K, Rowe H, Azzam H, et al. JOGC. 2016; 38(12):1127-37.

Authors do not have any conflicts of interest to declare.

Les auteurs n’ont aucun conflit d’intérêts à déclarer.